A. B. Sadegh
Jun 14, 2018
Citations
0
Influential Citations
1
Citations
Journal
Biomedical Journal of Scientific & Technical Research
Abstract
The main reason of postmenopausal osteoporosis is high bone turnover due to increased osteoclastic action) [1]. Strontium Ranelate is a new drug that is used for the treatment of postmenopausal osteoporosis [2]. It is used for decreasing the risk of fracture in vertebral and non-vertebral (especially hip) bones [3]. Strontium ranelate is a combination of strontium chloride (SrCl2, 6H2O) and sodium ranelate [4]. Strontium ranelate contains two stable atoms, strontium and one organic carrier, ranelic acid [5]. The molecular action mechanism of strontium ranelate is not understood [4]. But its action mechanism on bone is complex and time-dependent and dosedependent [6]. It has been seen that the low doses of strontium ranelate persuaded the bone tissue quality [7]. It enhances bone tissue quality, and is effective on bone resistance and reduces the fracture risk in postmenopausal osteoporotic patients which treated with strontium ranelate [8].